Dr David Meads
- Position: Professor of Health Economics
- Areas of expertise: HTA Decision modelling Early modelling to inform technology development and pricing Preference elicitation Health outcomes
- Email: D.Meads@leeds.ac.uk
- Phone: +44(0)113 343 0860
- Website: LinkedIn | Googlescholar
Profile
David is a co-applicant and lead health economist on a number of NIHR, charity and industry funded research projects. These include economic evaluations alongside clinical trials, decision-analytic modelling and stated preference studies. He is interested in exploring and improving decision making in healthcare at individual and organisational levels. He leads the haematology and surgical portfolios of research in AUHE. He has been a member of a NICE Technology Appraisal committee for over 7 years.
David's research interests include:
- Decision-analytic modelling and Health Technology Assessment
- Early economic modelling to inform research and investment decisions for pharmaceuticals and MedTech
- The valuation of health
- Stated preference elicitation and analysis
Current research
ARIEL: A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer with wild-type RAS and right primary tumour location
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial)
Generating a UK value set for the EQ-5D-5L
Randomised Phase III Trial Comparing Continuous with Intermittent Treatment Strategies in CLL (STATIC)
Using digital health to transform the management of long-term conditions in the NHS: Assessing real-world patient experience and empowerment and improvements to productivity and capacity (ASCELUS-H)
A randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma (DANTE)
A multicentre, randomised controlled trial of Laparoscopic versus Open Colorectal Surgery in the Acute Setting (LACES II)
Sustained exercise TrAining for Men with prostate caNcer on Androgen deprivation therapy (STAMINA)
Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Symptomatic Multiple Myeloma (FITNESS)
Phase III trial to assess a novel triplet IRDa in patients with newly diagnosed multiple myeloma not suitable for a stem cell transplant with randomisation according to frailty between standard therapy and dose adjusted therapy (Myeloma XIV – RADAR)
Teaching responsibilities
Module leader for Economic Evaluation for HTA module – Lucerne
PGDip Health Services Research – Module sessions: Decision-Analytic Modelling and Measurement and Valuation of Health
Professional activities
Member of the Health Economics Study Group
Member of the Centre for Decision Research, Leeds University Business School
Member of the Choice Modelling Centre, University of Leeds
Health economist member of an NIHR PGfAR funding panel
Member of the NICE Technology Appraisal Committee (D)
Qualifications
- PhD in Health Economics
Research groups and institutes
- Leeds Institute of Health Sciences
- Academic Unit of Health Economics
- Decision Modelling Group
- Health economics